CIK 0001651308 · Large accelerated filer
BeOne Medicines Ltd.
Sign in to watch- Ticker
- BEIGF
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 981209416
- Phone
- 41-616851900
- Business address
- C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, Switzerland, 4051
- Former names
- BeiGene, Ltd.
Securities
- ONC American Depositary Shares Nasdaq
- BEIGF Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $48,487,541
- in 9 filings, $47.8M under 10b5-1 plans
Net −$48,487,541. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-05 | Wang Lai Global Head of R&D | Grant or award | +69,251 | 990,171 | ||
| 2025-03-05 | Lee Chan Henry SVP, General Counsel | Grant or award | +40,209 | 246,142 | ||
| 2025-03-05 | Rosenberg Aaron Chief Financial Officer | Grant or award | +48,581 | 167,128 | ||
| 2025-03-04 | Wang Xiaodong Director | Sale 10b5-1 | −700 | $251.70 | $176K | 7,446 |
| 2025-03-04 | Wang Xiaodong Director | Sale 10b5-1 | −2,000 | $252.72 | $505K | 5,446 |
| 2025-03-04 | Wang Xiaodong Director | Sale 10b5-1 | −825 | $253.55 | $209K | 4,621 |
| 2025-03-04 | Wang Xiaodong Director | Sale 10b5-1 | −1,275 | $254.77 | $325K | 3,346 |
| 2025-03-04 | Wang Xiaodong Director | Sale 10b5-1 | −1,214 | $255.71 | $310K | 2,132 |
| 2025-03-04 | Wang Xiaodong Director | Sale 10b5-1 | −1,809 | $256.83 | $465K | 323 |
| 2025-03-04 | Wang Xiaodong Director | Sale 10b5-1 | −323 | $257.41 | $83K | 0 |
| 2025-03-03 | OYLER JOHN Chief Executive Officer | Option exercise | +1,220,531 | $0.50 | $610K | 4,199,364 |
| 2025-03-03 | OYLER JOHN Chief Executive Officer | Option exercise | +101,000 | $6.50 | $657K | 101,000 |
| 2025-03-03 | OYLER JOHN Chief Executive Officer | Sale | −5,956 | $240.53 | $1.4M | 95,044 |
| 2025-03-03 | OYLER JOHN Chief Executive Officer | Sale | −13,816 | $241.38 | $3.3M | 81,228 |
| 2025-03-03 | OYLER JOHN Chief Executive Officer | Sale | −8,192 | $242.46 | $2.0M | 73,036 |
| 2025-03-03 | OYLER JOHN Chief Executive Officer | Sale | −11,195 | $243.44 | $2.7M | 61,841 |
| 2025-03-03 | OYLER JOHN Chief Executive Officer | Sale | −4,910 | $244.45 | $1.2M | 56,931 |
| 2025-03-03 | OYLER JOHN Chief Executive Officer | Sale | −18,386 | $244.56 | $4.5M | 38,545 |
| 2025-03-03 | OYLER JOHN Chief Executive Officer | Sale | −1,090 | $245.36 | $267K | 37,455 |
| 2025-03-03 | OYLER JOHN Chief Executive Officer | Sale | −19,232 | $245.51 | $4.7M | 18,223 |
Page 31 of 71 · 1,406 trades